Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 8, 2019 | Post-IPO Equity | $800M | 1 | Regeneron | — | Detail |
Mar 28, 2011 | Post-IPO Equity | $10M | 1 | Takeda | — | Detail |
Jul 7, 2003 | Private Equity(PE) | $24.60M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Regeneron | Yes | Post-IPO Equity |
Takeda | Yes | Post-IPO Equity |
Merck | — | Private Equity(PE) |
ARCH Venture Partners | — | Private Equity(PE) |